Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
American Journal of Hematology|January 6, 2023
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 studyJean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy, et al.
Nature Cancer|February 28, 2022
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncologyDavid Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical studyJean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, et al.
JCO Precision Oncology|March 2, 2023
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid TumorsMihaela Aldea, Marco Tagliamento, Arnaud Bayle, et al.
Journal for Immunotherapy of Cancer|December 5, 2019
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive studyGuillaume Manson, Alexandre Thibault Jacques Maria, Florence Poizeau, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamicsLaura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 6, 2022
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersCapucine Baldini, Francois-Xavier Danlos, Andreea Varga, et al.
Pageof 3